Satellos Bioscience (MSLE) vs Nkarta (NKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nkarta (NKTX) has outperformed Satellos Bioscience (MSLE) over the past year, gaining 10.2% versus a gain of 5.4%. Over five years, MSLE leads with a -48.9% price change compared with -87.6% for NKTX. Nkarta is the larger company by market cap ($158.6 million vs $155.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MSLE | NKTX |
|---|---|---|
| Share price | $7.35 | $2.22 |
| Market cap | $155.94M | $158.65M |
| 1-day change | -3.67% | -2.42% |
| YTD return | +29.76% | +22.70% |
| 1-year return | +5.44% | +10.19% |
| 5-year return | -48.93% | -87.62% |
| EPS (TTM) | $-1.95 | $-1.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.40 | $3.72 |
| 52-week low | $5.30 | $1.70 |
| Distance from 52-week high | -45.13% | -40.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +257.14% | +388.94% |
| Average volume | 51.29K | 617.86K |
| Shares outstanding | 21.22M | 71.62M |
| Employees | 18 | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Satellos Bioscience
MSLE stock →Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo.
Health Care · Biotechnology: Pharmaceutical Preparations · 18 employees
About Nkarta
NKTX stock →Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
MSLE vs NKTX FAQ
Which is bigger, Satellos Bioscience or Nkarta?
Nkarta (NKTX) is larger, with a market capitalization of $158.65M compared with $155.94M for Satellos Bioscience (MSLE).
Which stock has performed better over the past year, MSLE or NKTX?
NKTX returned +10.19% over the past 12 months, compared with +5.44% for MSLE (price return, excluding dividends). Past performance does not predict future results.
Are Satellos Bioscience and Nkarta in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.